Enhanced release of adenosine in rat hind paw following spinal nerve ligation: involvement of capsaicin-sensitive sensory afferents.
Modulation of endogenous adenosine levels by inhibition of adenosine metabolism produces a peripheral antinociceptive effect in a neuropathic pain model. The present study used microdialysis to investigate the neuronal mechanisms modulating extracellular adenosine levels in the rat hind paw following tight ligation of the L5 and L6 spinal nerves. Subcutaneous injection of 50 microl saline into the nerve-injured paw induced a rapid and short-lasting increase in extracellular adenosine levels in the subcutaneous tissues of the rat hind paw ipsilateral to the nerve injury. Saline injection did not increase adenosine levels in sham-operated rats or non-treated rats. The adenosine kinase inhibitor 5'-amino-5'-deoxyadenosine and the adenosine deaminase inhibitor 2'-deoxycoformycin, at doses producing a peripheral antinociceptive effect, did not further enhance subcutaneous adenosine levels in the nerve-injured paw. Systemic pretreatment with capsaicin, a neurotoxin selective for small-diameter sensory afferents, markedly reduced the saline-evoked release of adenosine in rat hind paw following spinal nerve ligation. Systemic pretreatment with 6-hydroxydopamine, a neurotoxin selective for sympathetic afferent nerves, did not affect release. These results suggest that following nerve injury, peripheral capsaicin-sensitive primary sensory afferent nerve terminals are hypersensitive, and are able to release adenosine following a stimulus that does not normally evoke release in sham-operated or intact rats. Sympathetic postganglionic afferents do not appear to be involved in such release. The lack of effect on such release by the inhibitors of adenosine metabolism suggests an altered peripheral adenosine system following spinal nerve ligation.
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7. xuejun.liu@utoronto.ca
X J
XJ
Liu
T D
TD
White
J
J
Sawynok
D000241:Adenosine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000243:Adenosine Deaminase / Q000378:metabolism; D058892:Adenosine Deaminase Inhibitors; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism; D000344:Afferent Pathways / Q000187:drug effects / Q000293:injuries / Q000378:metabolism*; D000818:Animals; D002211:Capsaicin / Q000494:pharmacology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006930:Hyperalgesia / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009409:Nerve Crush; D036421:Nerve Fibers, Unmyelinated / Q000187:drug effects / Q000378:metabolism; D009437:Neuralgia / Q000378:metabolism* / Q000503:physiopathology; D009475:Neurons, Afferent / Q000187:drug effects / Q000378:metabolism*; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism*; D016627:Oxidopamine / Q000494:pharmacology; D059348:Peripheral Nerve Injuries; D010525:Peripheral Nerves / Q000187:drug effects / Q000378:metabolism*; D010523:Peripheral Nervous System Diseases / Q000378:metabolism* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000294:innervation / Q000378:metabolism; D013127:Spinal Nerves / Q000187:drug effects / Q000293:injuries / Q000378:metabolism; D017779:Sympathetic Fibers, Postganglionic / Q000187:drug effects / Q000378:metabolism
D058892:Adenosine Deaminase Inhibitors; D004791:Enzyme Inhibitors; D016627:Oxidopamine; D000248:Adenosine Kinase; D000243:Adenosine Deaminase; D000241:Adenosine; D002211:Capsaicin